Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Burning Rock Biotech Limited BNR

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal...


Recent & Breaking News (NDAQ:BNR)

Burning Rock Announces Results of 2022 Annual General Meeting

GlobeNewswire September 8, 2022

Burning Rock Reports Second Quarter 2022 Financial Results

GlobeNewswire August 31, 2022

Burning Rock Provides Second Quarter 2022 Business Updates and Schedules Earnings Release on August 31, 2022

GlobeNewswire August 4, 2022

Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022

GlobeNewswire August 3, 2022

Burning Rock Announces Resignation of Director

GlobeNewswire July 14, 2022

Burning Rock Announces the Launch of China's First Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study

GlobeNewswire June 30, 2022

Burning Rock Announces Changes to Board Composition

GlobeNewswire June 24, 2022

Burning Rock Announces US$10 Million Share Repurchase Program

GlobeNewswire June 21, 2022

Burning Rock Announces Plan to Pursue An Alternative Listing

GlobeNewswire June 21, 2022

Burning Rock Presents Latest Clinical Data from THUNDER Study at 2022 ASCO Annual Meeting

PR Newswire June 15, 2022

Burning Rock Receives CE Mark for its OverC(TM) Multi-Cancer Detection Blood Test Kit

PR Newswire June 1, 2022

Burning Rock Reports First Quarter 2022 Financial Results

GlobeNewswire May 31, 2022

Burning Rock Schedules First Quarter of 2022 Earnings Release on May 31, 2022

GlobeNewswire May 16, 2022

Burning Rock Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 21, 2022

Burning Rock Secures Second NGS Kit Approval from the NMPA

GlobeNewswire March 15, 2022

Burning Rock to Release MRD Clinical Data on NSCLC and CRC at the Upcoming American Association for Cancer Research Annual Meeting

GlobeNewswire March 15, 2022

Burning Rock Schedules Fourth Quarter and Full Year 2021 Earnings Release on March 22, 2022

GlobeNewswire February 21, 2022

Burning Rock Reaffirms 2021 Revenue Guidance of RMB500 Million

GlobeNewswire December 28, 2021

Burning Rock Announces Results of 2021 Annual General Meeting

GlobeNewswire December 27, 2021

Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock's OncoCompass Target(TM)

GlobeNewswire November 17, 2021